Alanyl Glutamine

Alanyl Glutamine

SCHEMBL1009705

CC(N)C(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 1/20 0.59
KMT2A Q03164 2/20 0.47
ALOX15 P16050 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
DPP4 P27487 1/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
FOLH1 Q04609 4/20 0.46
CA2 P00918 4/20 0.44
CA1 P00915 3/20 0.44
NAALAD2 Q9Y3Q0 2/20 0.44
RIMKLA Q8IXN7 1/20 0.44
ECE1 P42892 2/20 0.44
BMP1 P13497 1/20 0.43
ACE P12821 1/20 0.41
PRSS1 P07477 2/20 0.40
TMPRSS15 P98073 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alanyl Glutamine SCHEMBL133886 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL31140886 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL28215332 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL4274839 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL8427100 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL8813935 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL133887 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL29804717 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL21518502 0.98 NOD1 (0.58) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL21518470 0.98 NOD1 (0.58) NOD1KMT2AALOX15BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257330-A1 Multipurpose Compositions for Collecting and Transporting Biological Material LONGHORN VACCINES AND DIAGNOSTICS, LLC (US) 2025-08-14 US claimed
EP-4568500-A1 HYDRATION COMPOSITION Unilever IP Holdings B.V. (NL) 2025-06-18 EP claimed
CN-120130466-A Cornea endothelial cell protecting liquid for reducing metabolism of cornea endothelial cells 山东第一医科大学附属眼科医院(山东省眼科医院) 2025-06-13 CN claimed
CN-116064375-B Proliferation culture medium and proliferation culture method for primary pig liver cells 广东乾晖生物科技有限公司 2025-05-16 CN claimed
CN-118542316-B Cornea endothelial cell protection liquid containing antioxidant 山东第一医科大学附属眼科医院(山东省眼科医院) 2025-04-25 CN claimed
WO-2024256144-A1 BEVERAGE POWDERS WITH DESIRABLE COLOR UNILEVER IP HOLDINGS B.V. (NL) 2024-12-19 WO claimed
CN-119120381-A Method for rapidly generating CAR-T cells by using mesenchymal stem cell-derived engineering exosome-mediated mRNA 博雅干细胞科技有限公司 2024-12-13 CN claimed
CN-118995608-A Bionic material containing brain organoids and preparation method and application thereof 浙江大学医学院附属第一医院(浙江省第一医院) 2024-11-22 CN claimed
US-20240373840-A1 METHODS, SYSTEMS AND COMPOSITIONS FOR RESTORATION AND PRESERVATION OF INTACT ORGANS IN A MAMMAL YALE UNIVERSITY (US) 2024-11-14 US claimed
CN-118805774-A Cornea metaphase preservation solution containing high molecular dextran 山东第一医科大学附属眼科医院(山东省眼科医院) 2024-10-22 CN claimed
US-8445466-B2 Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof ENERGY BEVERAGES LLC 2013-05-21 US claimed
WO-2012078270-A2 EFFICIENT AND EFFECTIVE SUPPLEMENT SCREENING FOR THE DEVELOPMENT OF CHEMICALLY DEFINED MEDIA IN CELL CULTURE ABBOTT LABORATORIES (ES) 2012-06-14 WO claimed
EP-2377578-A1 Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof Owoc, John H. (US) 2011-10-19 EP claimed
US-20110251280-A1 Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof ENERGY BEVERAGES LLC 2011-10-13 US claimed
EP-2268805-A1 LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE Halozyme, Inc. (US) 2011-01-05 EP claimed
WO-2009111066-A1 LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE HALOZYME, INC. (US) 2009-09-11 WO claimed
CN-101151369-A Dipeptide crystals and process for production thereof KYOWA HAKKO KOGYO KK (JP) 2008-03-26 CN claimed
EP-1868430-A2 COMPOSITION AND METHOD FOR IN VITRO PRESERVATION OF CORNEAL TISSUES Cleo Cosmetic and Pharmaceutical Co., LLC (US) 2007-12-26 EP claimed
WO-2006110552-A2 COMPOSITION AND METHOD FOR IN VITRO PRESERVATION OF CORNEAL TISSUES CLEO COSMETIC AND PHARMACEUTICAL CO., LLC (US) 2006-10-19 WO claimed
US-5374551-A Measurement of metabolism of alpha-methyl glucoside BIOLOG, INC. (US) 1994-12-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251280-A1 Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof REN, CKMT1A; CKMT1B, GLS NOD1 4059/4885KMT2A 2867/4885ALOX15 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.